Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.

Wang H, Ghosh A, Baigude H, Yang CS, Qiu L, Xia X, Zhou H, Rana TM, Xu Z.

J Biol Chem. 2008 Jun 6;283(23):15845-52. doi: 10.1074/jbc.M800834200.

2.

[Gene therapy of ALS with RNA interference].

Yokota T.

Rinsho Shinkeigaku. 2009 Nov;49(11):821-3. Review. Japanese.

PMID:
20030220
3.

[Gene therapy of ALS with short interfering RNA].

Yokota T.

Brain Nerve. 2007 Oct;59(10):1187-94. Review. Japanese.

PMID:
17969360
4.

RNAi silencing in mouse models of neurodegenerative diseases.

Farah MH.

Curr Drug Deliv. 2007 Apr;4(2):161-7. Review.

PMID:
17456035
5.

Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis.

Valentine JS, Doucette PA, Zittin Potter S.

Annu Rev Biochem. 2005;74:563-93. Review.

PMID:
15952898
6.

Amyotrophic lateral sclerosis and gene therapy.

Miller TM, Smith RA, Cleveland DW.

Nat Clin Pract Neurol. 2006 Sep;2(9):462-3. Review. No abstract available.

PMID:
16932606
7.
8.

Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life.

Brooks BR.

Ann Neurol. 2009 Jan;65 Suppl 1:S17-23. doi: 10.1002/ana.21544. Review.

PMID:
19191306
9.

Short interfering RNA (siRNA) as a novel therapeutic.

Pushparaj PN, Melendez AJ.

Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):504-10. Review. Retraction in: Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305.

PMID:
16700886
11.

Superoxide dismutase-1 mutation-related neurotoxicity in familial amyotrophic lateral sclerosis.

Shibata N, Hirano A, Yamamoto T, Kato Y, Kobayashi M.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Jun;1(3):143-61. Review.

PMID:
11464949
12.

Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.

Nizzardo M, Simone C, Falcone M, Riboldi G, Rizzo F, Magri F, Bresolin N, Comi GP, Corti S.

Cell Mol Life Sci. 2012 May;69(10):1641-50. doi: 10.1007/s00018-011-0881-5. Review.

PMID:
22094924
13.

Mechanism and treatment of motoneuron degeneration in ALS: what have SOD1 mutants told us?

Xu Z.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Sep;1(4):225-34. Review.

PMID:
11465016
14.

Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

Turner BJ, Talbot K.

Prog Neurobiol. 2008 May;85(1):94-134. doi: 10.1016/j.pneurobio.2008.01.001. Review.

PMID:
18282652
15.

A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies.

Yamamoto M, Tanaka F, Tatsumi H, Sobue G.

Expert Opin Pharmacother. 2008 Aug;9(11):1845-57. doi: 10.1517/14656566.9.11.1845 . Review.

PMID:
18627324
16.

Adeno Associated Viral Vector Delivered RNAi for Gene Therapy of SOD1 Amyotrophic Lateral Sclerosis.

Stoica L, Sena-Esteves M.

Front Mol Neurosci. 2016 Aug 2;9:56. doi: 10.3389/fnmol.2016.00056. Review.

17.

RNA-targeted Therapeutics for ALS.

Reddy LV, Miller TM.

Neurotherapeutics. 2015 Apr;12(2):424-7. doi: 10.1007/s13311-015-0344-z. Review.

18.

Stem cells for the treatment of neurodegenerative diseases.

Dantuma E, Merchant S, Sugaya K.

Stem Cell Res Ther. 2010 Dec 10;1(5):37. doi: 10.1186/scrt37. Review.

Supplemental Content

Support Center